Dr. Puzantian, who joined KGI in January 2016, is Professor of Clinical Sciences at Keck Graduate Institute School of Pharmacy and Health Sciences. Prior to joining KGI, she was a clinical psychopharmacology consultant in private practice, collaborating with psychiatrists throughout the U.S. to provide expert guidance for challenging clinical cases. Previously, Dr. Puzantian was a psychiatric clinical pharmacy specialist and an Associate Clinical Professor at San Francisco General Hospital and at the University of California, San Francisco for nine years. She received her BS in Psychobiology from UCLA and her PharmD from the UCSF School of Pharmacy. She completed a psychiatric pharmacy practice residency at LA County/USC where she was honored as Pharmacy Resident of the Year. Over the course of her teaching career, Dr. Puzantian has been recognized with several teaching awards.
Dr. Puzantian was in the first group of specialists to become a Board Certified Psychiatric Pharmacist and has, in the past, served as the Chair of the Specialty Council on Psychiatric Pharmacy for the Board of Pharmaceutical Specialties. She is an active member of the College of Psychiatric and Neurologic Pharmacists (CPNP) and co-advisor to the KGI student chapter of CPNP. She currently practices as a psychiatric pharmacy specialist at Adventist Health Glendale. Dr. Puzantian also serves as Deputy Editor for the Carlat Psychiatry, Child Psychiatry, and Addiction Treatment Reports.
Puzantian T, Gasper JJ. Provision of naloxone without a prescription by California pharmacists 2 years after legislation implementation. JAMA 2018; 320(18):1933-1934.
Feder JD, Tien E, Puzantian T. Child Medication Fact Book for Psychiatric Practice. Newburyport, MA: Carlat Publishing; 2018. ISBN: 978-0-9975106-9-0.
Puzantian T, Gasper JG. Opioid Safety: Focus on Furnishing Naloxone. A Guide for California Community Pharmacists. Claremont, CA. June 2018.
Puzantian T, Carlat D. Medication Fact Book For Psychiatric Practice. 4th ed. Newburyport, MA: Carlat Publishing; 2018. ISBN: 978-0-9975106-6-9.
CPNP Substance Abuse Task Force. OPIOID USE DISORDERS: Interventions for Community Pharmacists 2016; http://cpnp.org/guideline/opioid (guideline).
Puzantian T. Chapter 28 – Pharmaceutical Care Competencies: Psychiatric Patients. Murdaugh, LB (ed). In Competence Assessment Tools for Health-System Pharmacies, 5th edition; 2015. ISBN: 978-1-58528-402-3
CPNP Substance Abuse Task Force. NALOXONE ACCESS: A Practical Guideline for Pharmacists 2015; http://cpnp.org/guideline/naloxone (guideline).
Puzantian T. “Anxiety Disorders” Chapter 52 in Helms RA and Quan DJ (eds) Textbook of Therapeutics: Drug and Disease Management, 8th edition; 2006. ISBN: 0-7817-5734-7
Tsai C, Puzantian T. Liquid risperidone in the treatment of psychotic agitation. CNS Drugs 2002;16(11):777.778.
Puzantian T. Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy 2002;22(7):930-933.
Pham JV, Puzantian T. Ecstasy: dangers and controversies. Pharmacotherapy 2001;21(12):1561-1565.
Augustin SG, Puzantian T, Caley CF, Marken PA, Richards AL, Levin GM. Psychiatric Pharmacists. American Journal of Psychiatry 2001;158(12):2090. (letter)
Puentes E, Puzantian T, Lum BL. Prediction of valproate serum concentrations in adult psychiatric patients using Bayesian model estimations with NPEM2 population pharmacokinetic parameters. Therapeutic Drug Monitoring 1999;21(3):351-354.
Puzantian T, Kawase K. Does the addition of pindolol accelerate or enhance the response to selective serotonin reuptake inhibitor antidepressants? Pharmacotherapy 1999;19(2):205-212.